Pari eFlow rapid Quick Reference Manual page 2

Practitioner´s information: Inhalation therapy with eFlow
Inhalation Solutions & Treatment Time
Active Agent
1)
Concentration
Tobramycin
300 mg/5 ml
Colistimethate sodium
79 mg (1 Mio units) /3 ml
Salbutamol
2.5 mg / 2.5 ml
Ipratropiumbromide
500 μg / 2 ml
Dornase alfa
2.5 mg / 2.5 ml
Acetylcysteine
300 mg / 3 ml
Medical product:
Isotonic sodium chloride
solution (0.9 %) 2.5 ml
PARI NaCl Inhalation Solution
Dispensed hypertonic
saline solution
(Sodium chloride 5.8%) 2.5 ml
1) These agents are approved for inhalation therapy in Germany.
Substance
1)
Class
Aminoglycoside Serum level is comparable to standard therapy using
the PARI LC PLUS
Antibiotic
1 μg / ml data on file (n=9).
Tested with TOBI
Polymyxine Colistin powder has to be dissolved carefully in 3 ml
0.9 % sodium chloride solution.
Polypeptide Antibiotic
Tested with Colistin CF (Grünenthal)
Bronchodilator Comparable treatment safety: Heart rate pre and post
delivery of Salbutamol (10 min after inhalation) is
Beta 2 mimetic
comparable to LC PLUS
Tested with Sultanol
Bronchodilator Tested with Atrovent
Anticholinergic
Mucolytic agent Enzymatic activity remains largely stable
after nebulization (90%) as for PARI LC PLUS
nebuliser
Mucolytic Tested with Fluimucil
Secretolytic Individual treatment schedule.
Tested with PARI NaCl Inhalation Solution
Secretolytic Individual treatment schedule.
Tested with dispensed saline solution 5.8 %
2) Seemann et al: Improving aerosol drug delivery in CF therapy. European Cystic Fibrosis Society, 28 th European Cystic Fibrosis
Conference, Crete, Greece, June 22-25, 2005. 3) Lichtinghagen (2004 and 2005), MHH. 4) PARI internal tests, measured with the
Malvern MasterSizer X at 23°C and 50% relative humidity. Inspiratory flow 20 l/min. TOR, MMD, RF, time (mean values).
® rapid:
®
rapid
eFlow
Details
®
nebuliser. Serum value approx.
2)
®
(Chiron/Novartis)
®
nebuliser. Data on file (n=10).
®
forte (Glaxo Smith Kline)
® (Boehringer Ingelheim)
®
2)3) . Tested with Pulmozyme ® (Roche)
®
(Zambon)
TOR MMD RF %
4) 4) 4)
g/min μm < 5μm
0.50 3.9 73
0.58 3.9 69
0.68 4.3 64
2)
0.69 4.3 63
0.61 3.9 72
0.60 4.1 70
0.70 4.3 67
0.69 4.2 69
Time
Min
6-8
3-4
2-3
1-2
2-3
4-5
2-3
2-3